
ACT Brief: Zip Code Trial Access, Smaller Biotech APAC Perceptions, and Pimjetmi Tumor Approval
11/13/2026
0:00
1:30
In today’s ACT Brief, we examine how ZIP code shapes trial availability and enrollment, why smaller biotechs hold outdated views of APAC sites, and how FDA approved Pimjetmi for symptomatic tenosynovial giant cell tumor.
More episodes from "Applied Clinical Trials"



Don't miss an episode of “Applied Clinical Trials” and subscribe to it in the GetPodcast app.








